Valuation: Mylan N.V.

Market Cap 21.86B 19.6B 18.04B 16.33B 30.55B 2,076B 31.1B 215B 86.21B 1,092B 82.04B 80.3B 3,444B P/E 2026 *
82.6x
P/E 2027 * 50.9x
Enterprise Value 33.53B 30.06B 27.66B 25.04B 46.85B 3,184B 47.7B 329B 132B 1,674B 126B 123B 5,282B EV / Sales 2026 *
2.27x
EV / Sales 2027 * 2.14x
Free-Float
91.44%
Yield 2026 *
2.62%
Yield 2027 * 2.74%
Manager TitleAgeSince
Chief Executive Officer 63 31/03/2023
Director of Finance/CFO 59 07/05/2026
Chief Tech/Sci/R&D Officer - 14/12/2023
Director TitleAgeSince
Director/Board Member 78 15/11/2020
Director/Board Member 78 15/11/2020
Director/Board Member 62 15/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.37% - - 21.86B
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +2.07%+5.90%+46.59%+83.14% 473.55B
Weighted average by Cap. +2.01%+6.60%+50.88%+98.31%

Financials

2026 *2027 *
Net sales 14.78B 13.25B 12.19B 11.04B 20.65B 1,403B 21.02B 145B 58.28B 738B 55.46B 54.28B 2,328B 15.22B 13.64B 12.56B 11.37B 21.27B 1,445B 21.65B 149B 60.02B 760B 57.12B 55.9B 2,398B
Net income 142M 127M 117M 106M 198M 13.44B 201M 1.39B 558M 7.07B 531M 520M 22.29B 298M 267M 246M 223M 417M 28.33B 424M 2.93B 1.18B 14.9B 1.12B 1.1B 47B
Net Debt 11.67B 10.46B 9.63B 8.71B 16.3B 1,108B 16.6B 115B 46.01B 583B 43.79B 42.85B 1,838B 10.76B 9.65B 8.88B 8.04B 15.04B 1,022B 15.31B 106B 42.44B 537B 40.39B 39.53B 1,695B
Logo Mylan N.V.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Mylan N.V.